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International Prostate Symptom Score (IPSS), International 
Index of Erectile Function (IIEF-5) and adverse events were 
reported at day 7, month 1, 3, and 6.
Results Month 6 negative biopsy rate was 68.4 % in the 
overall evaluable population (N = 114) and 80.6 % for 
patients treated by hemiablation with light density index 
(LDI) ≥ 1 (N = 67). Mean prostate necroses at week-1 
were 76.5 and 86.3 %, respectively. In both groups, PSA 
levels at month 6 decreased by 2.0 ng/mL. Small changes 
from baseline for IPSS and IIEF-5 indicated a slight 
improvement in urinary function and a slight deterioration 
in sexual function.
Conclusions Focal VTP treatment with TOOKAD® Solu-
ble at 4 mg/kg and 200 J/cm resulted in a negative 6-month 
biopsy rate of 68.4 % for the whole population and 80.6 % 
for patients treated by hemiablation with LDI ≥ 1. The 
treatment was well tolerated. Two phase III studies will 
reach completion in early 2015.
Abstract 
Purpose To evaluate the 6-month effects of the recom-
mended drug and light dosage in focal vascular-targeted 
photodynamic therapy (VTP) using TOOKAD® Soluble in 
patients with localized prostate cancer (LPCa).
Methods We performed a pooled analysis of 117 men with 
LPCa, PSA <10 ng/mL, and Gleason score ≤7 (3 + 4), from 
3 studies who received a 10-min intravenous infusion of a 
single dose of 4 mg/kg TOOKAD® Soluble, activated by a 
753-nm light at 200 J/cm delivered in the prostate by trans-
perineal fibres under transrectal ultrasound guidance. Pri-
mary endpoint was 6-month negative biopsies in the treated 
lobe(s). PSA was measured at month 1, 3, and 6. Magnetic 
resonance imaging was performed at day 7, month 3, and 6. 
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Introduction
Currently, men who are diagnosed with early-stage pros-
tate cancer face a difficult decision on their initial treat-
ment. The current treatment choice for localized PCa lies 
between active surveillance and radical therapies [1, 2]. 
However, whole gland treatment may be unnecessarily 
aggressive [3–5], while active surveillance may not be suit-
able in a subset of patients with higher-risk disease [6]. 
Radical treatments of the prostate, such as radiotherapy and 
surgery, are associated with an important burden of side 
effects and long-term toxicities [3], and their use in early-
stage prostate cancer is linked to overtreatment. For a sub-
set of prostate cancer patients, there is a clear need for an 
alternative approach and interest has been renewed in focal 
therapy [7], which aims at selective ablation of the tumour 
and local control without the comorbidities frequently 
associated with whole gland treatment.
TOOKAD® Soluble vascular-targeted photodynamic 
(VTP) therapy is a minimally invasive technique used as 
a focal therapy for patients with early prostate cancer. Its 
mode of action depends on three essential components: a 
light-sensitive drug to enhance the sensitivity of tumour 
vasculature to light energy; light of a specific wavelength; 
and sufficient oxygen to drive the reaction. Once optical 
fibres within hollow plastic needles are accurately posi-
tioned in the prostate, light of a specific wavelength is 
delivered through these fibres and activates an intrave-
nously administered photosensitizer in the prostate. This 
generates reactive oxygen species (ROS) that activate 
thrombosis within the blood vessels. This photodynamic 
reaction results in obliteration of the vessel anatomy 
with resultant deprivation of oxygen and nutrients to the 
tumour cells and surrounding prostate tissue in the treated 
area.
TOOKAD® Soluble (WST11, padeliporfin; palladium 
bacteriopheophorbide monolysotaurine) is a novel photo-
sensitizers of the bacteriochlorophyll derivatives family. 
Unlike the previous compound (WST09) which needed sol-
ubilizing excipient Cremophor® [8, 9], TOOKAD® Soluble 
is soluble in aqueous solutions. TOOKAD® Soluble pre-
sents minimal extravasation from the circulation and there-
fore remains confined to the vasculature even at high doses; 
it is rapidly cleared by hepatic and renal systems [10, 11]. 
Preclinical studies in several animal models have shown 
that treatment with TOOKAD® Soluble leads to occlusion 
of the entire tumour vasculature within a few minutes of 
treatment, leading to tumour ablation [12–15].
A recently published retrospective analysis of 28 
patients, treated with TOOKAD® Soluble in multicen-
tre trials [16], proposed a semi-empirical model based on 
three parameters of photodynamic therapy: dose of drug, 
energy fluence, and delivery time. This analysis was able to 
establish a correlation between the illuminated volume of 
prostate tissue and the necrosis as measured on day 7 mag-
netic resonance imaging (MRI) scan. Subsequently, three 
pilot studies of focal treatment with TOOKAD® Soluble in 
patients with localized prostate cancer established that the 
parameters for the optimal photosensitizer and light com-
bination to give maximum ablation of malignant prostatic 
tissue were 4 mg/kg TOOKAD® Soluble activated by 753-
nm light at a dose of 200 J/cm [17, 18]. The present paper 
reports the findings of a pooled analysis of these three stud-
ies. It was designed to more reliably evaluate the efficacy 
and safety of the recommended study drug and light dosage 
combination.
Methods
Studies and patients included in the meta-analysis
The three studies included in the pooled analysis (PCM201, 
PCM202, and PCM203) all looked at the efficacy of vari-
ous combinations of light energy and TOOKAD® Solu-
ble doses (Table 1). Having established that TOOKAD® 
Soluble at the dose of 4 mg/kg combined with a light 
energy of 200 J/cm at 730 nm provided the optimal con-
ditions of treatment, in terms of efficacy and safety, only 
patients dosed with this combination were included in the 
pooled analysis. Patients who did not receive any amount 
of TOOKAD® Soluble, or who received other doses of 
TOOKAD® Soluble or other light energies were excluded.
Inclusion criteria for the individual studies
The main inclusion and exclusion criteria for the indi-
vidual studies were the same as reported in PCM201 [17] 
and PCM203 studies [18]. Dynamic contrast MRI was 
performed in all patients. PSA level had to be <10 ng/mL 
at entry. In PCM201 and PCM203, for men diagnosed by 
transperineal template guided biopsy, secondary Gleason 
pattern 4 was permitted provided that it was low burden 
(<3 cores positive per lobe and ≤3 mm maximum cancer 
core length). No restrictions were placed on the number of 
positive cores present at baseline in PCM201 or PCM203. 
In PCM202, ≤50 % of sampled cores were to be positive, 
each positive core having a tumour length of ≤5 mm, and 
only patients with unilateral disease at entry were included.
All the studies were conducted according to Good Clini-
cal Practice (CPMP/ICH) regulations and the Declaration 
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of Helsinki and subsequent amendments, and the protocols 
were approved by the ethics committees or institutional 
review boards at all participating centres. All patients gave 
their written informed consent to participate before any 
study-related activities were performed.
TOOKAD® Soluble VTP procedure
The details of the procedure have already been described 
in previous publications [17–20]. Regarding the population 
analysed TOOKAD® Soluble treatment comprised a single 
IV administration of TOOKAD® Soluble (STEBA Biotech, 
L–2613 Luxembourg) at a dose of 4 mg/kg, followed by 
local illumination of the targeted zone using a using 753-
nm laser light at a fixed power (150 mW/cm) and energy 
(200 J/cm) delivered through transperineal interstitial 
optical fibres positioned in the prostate. These fibres were 
inserted under ultrasound guidance according to a treat-
ment plan based on the MRI and the prostate biopsies. The 
treatment consisted in a hemiablation (treatment of only 
one lobe of the prostate) for patients with unilateral disease 
at entry or in a conservative subtotal ablation (treatment of 
both lobes) in case of bilateral disease. The total duration 
of the whole procedure was about 2 h (including anaesthe-
sia, fibre placement, and illumination with the laser light).
A urinary catheter was left in situ until the next morning. 
The patient was required to wear protective eyewear and 
stay in low level light for the 1 h after the treatment.
For all three trials, if the month 6 biopsy was negative, 
the patient was followed up per local standard of care. 
In case of positive month 6 biopsy, a retreatment with 
TOOKAD® Soluble VTP was proposed. The pooled anal-
yses were performed on the three trials when all patients 
reached their month 6 biopsy assessment. All analyses were 
based on individual patient data. The analysis of month 12 
data and of retreatment data was not included in the pooled 
analysis.
Assessments
Efficacy of the treatment was assessed by a 12-core pros-
tate biopsy, taken 6 months after TOOKAD® Soluble pro-
cedure. Success was defined as a negative biopsy in the 
treated lobe(s) that initially contained the tumour. The 
Table 1  Study design of the three studies included in the pooled analysis
Study number CLIN801 PCM201
ClinTrials.gov identifiers NCT00707356/
EudrAct or IND Number 2008-000876-26
Number of patients enroled 42
Number of patients treated at optimal dose 35
Study design Multicentre, phase II, open-label, single IV dose, 6-month clinical trial
TOOKAD® Soluble treatment Single, 10 min, IV administration, doses of 2 to 6 mg/kg, 753 nm laser light at a fixed power 
(150 mW/cm) and energy (200 J/cm)
Study number CLIN901 PCM202/
ClinTrials.gov identifiers NCT00946881/
EudrAct or IND Number IND 101,886
Number of patients enroled 30
Number of patients treated at optimal dose 21
Study design Prospective, multicentre, phase I/II, nonrandomized, open-label, single IV, escalating drug dose and 
light energy dosage clinical trial
TOOKAD® Soluble treatment Single, 10 min, IV administration, doses of either 2, 4 or 6 mg/kg, 753-nm laser light at escalating 
fixed energy doses of 200 J/cm and 300 J/cm, by escalating power at each energy to 167 mW/cm 
and 250 mW/cm, respectively
Study number CLIN902 PCM203/
ClinTrials.gov identifiers NCT00975429/
EudrAct or IND Number 2009-012809-19
Number of patients enroled 86
Number of patients treated at optimal dose 61
Study design Multicentre, phase II, open-label, single IV dose, 6-month, nonrandomized clinical trial
TOOKAD® Soluble treatment Part A: patients were assigned to treatment groups based on the prostate size (<60 cc received 4 mg/
kg WST11 and ≥60 cc received 6 mg/kg WST11). 200 J/cm light. Part B, patients were assigned 
to one of two treatment groups based on predefined criteria and received either 4 or 6 mg/kg 
WST11 and 200 or 300 J/cm light
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secondary efficacy criteria were (1) change from baseline 
in PSA levels at 1, 3, and 6 months and (2) the MRI result 
on day 7 and 6 months.
Adverse events (AEs) were reported, laboratory evalu-
ations were performed, and vital signs were measured 
periodically during the 6-month follow-up period; AEs 
were coded using the Medical Dictionary of Regulatory 
Activities, version 12.0 (PCM201) and 13.0 (PCM202 
and PCM203). AE severity was graded according to the 
National Cancer Institute’s Common Terminology Crite-
ria for AEs (CTCAE), version 4.0. The relationship of the 
AEs was assessed with respect to both the study treatment 
and the technical procedure. Urinary and erectile functions 
at baseline, and at 1, 3, and 6 months post-treatment, were 
assessed using the International Prostate Symptom Score 
(IPSS) and International Index of Erectile Function (IIEF-
5) quality-of-life questionnaires, respectively.
Data sets analysed
Three patient populations were defined: the efficacy popu-
lation included all patients who received the TOOKAD® 
Soluble procedure irrespective of any protocol deviation. 
The per protocol (PP) population included all patients 
from the efficacy population who received the entire pro-
cedure and had no major protocol deviations. The safety 
population included all patients who received the proce-
dure. Efficacy presentations were produced on the effi-
cacy population and repeated on the patients from the PP 
population with LDI ≥ 1. The LDI was defined as the ratio 
between total light-emitting length of inserted illuminating 
fibres (cm) and the baseline volume by planimetry (cm3) 
of targeted prostate (half the prostate volume for unilat-
eral treatment and the whole prostate volume for bilateral 
treatment).
Statistical methodology
Data were analysed using SAS (Version 9.1.3) and pre-
sented using descriptive statistics, with 95% confidence 
intervals (CIs) also being provided for the percentage 
of patients with a negative biopsy assessment and for the 
mean change from baseline in PSA values. If a patient 
discontinued the study in the 3-6 month period following 
the Day 1 visit, a biopsy was performed at the time of dis-
continuation. These biopsy results were analysed with the 
other Month 6 biopsies.
Missing values were not replaced (unless specified oth-
erwise) during the statistical analysis of safety or efficacy. 
No imputations were required for partial/missing dates for 
AEs. Baseline value was defined as the latest value prior to 
the first TOOKAD® Soluble treatment. When several meas-
urements were available at baseline, i.e. at screening or day 




A total of 117 men (mean age, 62.2 years) completed the 
entire TOOKAD® Soluble procedure at the recommended 
dose and were included in the efficacy and safety sets 
(35, 21, and 61 men from studies PCM201, PCM202, and 
PCM203, respectively); 109 men were included in the PP 
set. Two patients discontinued prior to month 6, one patient 
due to lack of efficacy and one patient withdrew his con-
sent. There were 38 men and 79 men, respectively, in the 
LDI < 1 and LDI ≥ 1 subgroups (Table 2).
All patients had at least one positive core at baseline. 
The mean [standard deviation (SD)] time since the baseline 
biopsy was 4.7 (2.3) months, and the mean number of posi-
tive scores was 2.0 (range, 1–10). Almost all patients (116 of 
117, 99.1 %) had a Gleason score of 3+3. Demographic and 




In the efficacy population, month 6 biopsies were available 
for 114 patients and 142 treated lobes. By month 6, 78 out 
of 114 patients (68.4 %) had negative biopsies (95 % CI 
59.1, 76.8 %) (Table 3). When the results were compared 
by LDI and laterality, men treated unilaterally with an 
LDI ≥ 1 fared the best, with 80.6 % of patients having a 
negative biopsy at month 6 (Table 3).
When the analyses were limited to the PP population 
treated with an LDI ≥ 1 (N = 76), the negative biopsy rate 
at month 6 was 77.6 % (95 % CI 66.6, 86.4 %) (Table 5), 
which was higher than seen in the overall efficacy popula-
tion (68.4 %).
Day 7 MRI and PSA results
The mean percentage of necrosis of the targeted prostate 
tissue was defined by the volume of necrosis at day 7 in 
the treated lobes or lobe divided by the mean of the pre- 
and post-treatment of the whole prostate volume or half 
the prostate volume, respectively. This derived volume 
was used as the prostate tends to swell after the treat-
ment, resulting in a larger prostate volume at day 7 than 
at baseline. Based on the MRI data, the mean percentage 
of necrotic prostate tissue on day 7 was 76.5 % (Table 4). 
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Radiological evidence of extraprostatic necrosis was 
reported in about two-third of the patients (67.2 %), and 
this was usually not associated with clinically significant 
disorders. Mean changes from baseline in PSA levels were 
−2.1 and −2.0 ng/mL, respectively, at 3 and 6 months 
(Table 4). The PSA results should be interpreted with cau-
tion as the treatment given in this study is not a whole 
gland treatment.
In the PP population with an LDI ≥ 1 (Table 5), the MRI 
scan at week 1 showed a mean percentage of necrotic tissue 
on day 7 of 86.3 %, with evidence of extraprostatic necro-
sis reported in approximately 77.3 % of patients. Mean 
changes from baseline in PSA levels were −2.3 ng/mL at 
both 3 and 6 months.
Treatment emergent adverse events
A total of 97 patients (82.9 %) reported 386 treatment 
emergent AEs (TEAEs) (Table 6). Treatment and proce-
dure were well tolerated, and the majority of TEAEs were 
of mild or moderate intensity (CTCAE grades 1 or 2). 
Overall, 61 patients (52.1 %) reported at least 1 TEAE that 
was considered related to study drug, 53 patients (45.3 %) 
reported at least 1 TEAE that was considered related to the 
Table 2  Patient disposition: overall, by study, and by LDI and laterality of treatment
LDI light density index
a Percentages are based on the number of patients included in the safety population
All studies By study By LDI and laterality
PCM201 PCM202 PCM203 LDI < 1 LDI ≥ 1
4 mg/kg 200 J/cm
Unilateral
4 mg/kg 200 J/cm
Bilateral
4 mg/kg 200 J/cm
Unilateral
4 mg/kg 200 J/cm
Bilateral
N = 117 N = 35 N = 21 N = 61 N = 20 N = 18 N = 68 N = 11
Efficacy/safety 
analysis sets
117 35 21 61 20 18 68 11
Per protocol set 109 29 21 59 18 15 65 11
Discontinued 
prior to month 
6a
2 (1.7) 1 (2.9) 0 1 (1.6) 1 (5.0) 0 1 (1.5) 0
Reason for dis-
continuation
n = 2 n = 1 n = 0 n = 1 n = 1 n = 0 n = 1 n = 0
Withdrew consent 1 (50.0) 0 0 1 (100) 0 0 1 (100) 0
Lack of efficacy 1 (50.0) 1 (100) 0 0 1 (100) 0 0 0
Table 3  Prostate biopsy results at month 6: overall and by LDI and laterality
If a patient discontinued the study prior to month 6 but more than 3 months following day 1, a biopsy was performed at the time of patient dis-
continuation. These biopsy results were included with the others
a For the percentage of patients with negative biopsy assessment
All studies By study By LDI and laterality
PCM201 PCM202 PCM203 LDI < 1 LDI ≥ 1
4 mg/kg  
200 J/cm
Unilateral
4 mg/kg  
200 J/cm
Bilateral
4 mg/kg  
200 J/cm
Unilateral
4 mg/kg  
200 J/cm
Bilateral
N = 117 N = 35 N = 21 N = 61 N = 20 N = 18 N = 68 N = 11
Prostate biopsy  
at month 6
114 34 21 59 19 17 67 11
Number (%) patients
 Positive biopsy 36 (31.6) 16 (47.1) 8 (38.1) 12 (20.3) 11 (57.9) 8 (47.1) 13 (19.4) 4 (36.4)
 Negative  
biopsy
78 (68.4) 18 (52.9) 13 (61.9) 47 (79.7) 8 (42.1) 9 (52.9) 54 (80.6) 7 (63.6)
 Exact 95 % CIa (59.1, 76.8) (35.1, 70.2) (38.4, 81.9) (67.2, 89.0) (20.3, 66.5) (27.8, 77.0) (69.1, 89.2) (30.8, 89.1)
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study device, and 90 patients (76.9 %) reported at least 1 
TEAE that was considered related to the technical proce-
dure. The most frequently reported TEAEs overall were 
dysuria (33.3 %), erectile dysfunction (16.2 %), perineal 
pain (15.4 %), haematuria (13.7 %), urinary retention 
(11.1 %), and micturition urgency (9.4 %); the majority of 
these commonly reported TEAEs were considered related 
to study drug, devices, or technical procedures of the study. 
No significant change in vital signs was observed.
No TEAEs led to study discontinuation or prema-
ture withdrawal from the study. Eleven patients (9.4 %) 
reported 11 serious TEAEs. Eight of them were considered 
as related to either study drug, study device or study proce-
dure, and three were not related. Among the eight-related 
serious TEAEs, there were two cases of “large extrapros-
tatic necrosis” reportedly due to a laser failure and two 
cases of “prostatitis”. All other related serious TEAEs were 
single occurrences (pelvic pain, haematuria, prostatic ure-
thra stricture and worsening of orchi-epididymitis).
There were no notable changes in the haematologi-
cal and biochemical parameters post-procedure, and the 
worst grades reported for most laboratory parameters 
Table 4  Post-treatment MRI 




N = 35 N = 21 N = 61 N = 117
Day 7 prostate MRI results, mean (SD)
 Prostate volume by planimetry (mL) 62.7 (24.2) 56.7 (23.4) 58.9 (18.4) 59.6 (21.1)
 Volume of necrosis by planimetry (mL) 19.5 (8.9) 18.4 (10.9) 26.0 (13.5) 23.0 (12.5)
 Percentage necrosis (%) 68.8 (34.5) 64.1 (25.3) 83.8 (20.9) 76.5 (26.6)
PSA levels (ng/mL), mean (SD)
 Baseline 5.6 (2.1) 3.7 (2.4) 6.2 (2.4) 5.6 (2.5)
 At 1 month 4.5 (3.1) 4.7 (4.0) 4.9 (3.8) 4.8 (3.6)
 Change from baseline at 1 month −1.1 (3.6) 0.9 (3.1) −1.2 (4.2) −0.8 (3.9)
 At 3 months 3.1 (1.8) 3.5 (3.4) 3.6 (2.2) 3.4 (2.3)
 Change from baseline at 3 months −2.6 (2.4) −0.1 (2.6) −2.5 (2.4) −2.1 (2.6)
 At 6 months 3.5 (3.2) 2.9 (2.2) 3.8 (2.5) 3.5 (2.7)
 Change from baseline at 6 months −2.1 (3.4) −0.8 (1.0) −2.4 (2.4) −2.0 (2.7)
Table 5  Post-treatment MRI 
characteristics and PSA levels 
(PP population with LDI ≥ 1)
Studies All studies
PCM201 PCM202 PCM203
N = 12 N = 15 N = 49 N = 76
Biopsy results at month 6
 Negative biopsy, n (%) 10 (83.3) 11 (73.3) 38 (77.6) 59 (77.6)
 Exact 95 % CI (51.6, 97.9) (44.9, 92.2) (63.4, 88.2)(66.6, 86.4)
Day 7 MRI results, Mean (SD)
 Prostate volume by planimetry (mL) 46.9 (9.3) 62.3 (19.4) 56.0 (18.6) 55.8 (18.0)
 Volume of necrosis by planimetry (mL) 17.9 (4.5) 21.5 (8.1) 24.3 (11.4) 23.0 (10.4)
 Percentage necrosis (%) 96.4 (25.0) 74.3 (15.3) 88.5 (18.6) 86.3 (19.6)
PSA (ng/mL) results, mean (SD)
 Baseline 5.8 (2.8) 4.0 (2.1) 6.1 (2.5) 5.6 (2.6)
 At 1 month 3.3 (3.2) 5.5 (4.4) 4.6 (2.9) 4.5 (3.3)
 Change from baseline at 1 month −2.4 (3.6) 1.3 (3.6) −1.5 (3.3) −1.1 (3.6)
 At 3 months 2.6 (2.5) 3.8 (3.6) 3.4 (1.9) 3.3 (2.4)
 Change from baseline at 3 months −3.2 (3.4) −0.1 (3.0) −2.7 (2.2) −2.3 (2.8)
 At 6 months 1.9 (1.7) 2.8 (1.8) 3.8 (2.6) 3.3 (2.4)
 Change from baseline at 6 months −3.8 (2.7) −1.2 (0.9) −2.3 (2.4) −2.3 (2.4)
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were CTCAE grade 1 or 2. There was no evidence of renal 
toxicity.
Quality-of-life questionnaires
Urinary and erectile functions were assessed with the IPSS 
and IIEF-5 (Fig. 1). For both measures, there were slight 
reductions in the sum of scores at 6 months post-treatment. 
The mean (SD) change from baseline at month 6 was −1.8 
(4.8) and −3.0 (7.0), for the IPSS and IIEF-5, respectively, 
indicating a slight improvement in urinary function and 
a slight deterioration in sexual function compared with 
baseline.
Discussion
Focal treatment with TOOKAD® Soluble may offer the 
potential to treat patients with early prostate cancer in a 
minimally invasive, targeted manner. It is a single session 
treatment, lending itself to administration in an ambulatory 
care setting and may be repeatable. The operative time of 
this technique is also one of the shortest of the anti-tumour, 
anti-vascular treatment modalities currently available 
[21, 22]. Because of the focal nature of delivery, and with 
TOOKAD® Soluble photo activation and ROS generation 
confined within the circulation, rather than being aimed at 
cellular components, damage to surrounding tissue is kept 
to a minimum. Thus, there is a reduction in the significant 
morbidity (e.g. urinary incontinence and erectile dysfunc-
tion) associated with radical therapies. Three prospective 
studies that investigated the optimal treatment conditions 
for TOOKAD® Soluble in early prostate cancer allowed to 
establish the recommended treatment conditions for pros-
tate cancer tumour ablation as 4 mg/kg TOOKAD® Solu-
ble activated by 753-nm light at a dose of 200 J/cm and a 
light density index of >1. The present pooled analysis of the 
biopsy, MRI, PSA, and safety data from 117 patients who 
were treated with those optimal treatment parameters in 
these three studies gives a better evaluation of the safety and 
efficacy of this dose/light combination, which can achieve 
prostate ablation in the majority of patients. Of the patients 
in the pooled analysis who had received the recommended 
treatment combination, 68.4 % had negative biopsy results 
Table 6  Summary of SAEs 
by NCI CTCAE toxicity 
grade, system organ class, and 
preferred term
System organ class/adverse event Severity (NCI CTCAE v4.0 toxicity grade)
Gr1 Gr2 Gr3 Gr4 Gr5 Total
All system organ class 2 7 2 0 0 11
Gastrointestinal disorders 0 1 0 0 0 1
 Haematemesis, oesophageal and duodenal ulcer 0 1 0 0 0 1
General disorders and administration site conditions 0 2 0 0 0 2
 Necrosis 0 2 0 0 0 2
Infections and infestations 0 0 1 0 0 1
 Orchitis 0 0 1 0 0 1
Renal and urinary disorders 0 2 1 0 0 3
 Urethral stenosis 0 0 1 0 0 1
 Dysuria 0 1 0 0 0 1
 Haematuria 0 1 0 0 0 1
Reproductive system and breast disorders 2 1 0 0 0 3
 Pelvic pain 1 0 0 0 0 1
 Prostatitis 1 1 0 0 0 2
Vascular disorders 0 1 0 0 0 1
 Deep vein thrombosis 0 1 0 0 0 1
Fig. 1  Mean IIEF-5 and IPSS (Questions 1–7) scores for PP patients 
with LDI ≥ 1
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at month 6. For these patients, the necrosis percentage was 
76.5 % at day 7. When these analyses were confined to 
patients in the PP set who had been treated with an LDI ≥ 1, 
the month 6 negative biopsy rate improved to 77.6 % and 
the necrosis percentage to 86.3 % at day 7. These results 
confirm results from the exploratory analysis in the individ-
ual studies that efficacy was improved when the LDI ≥ 1.
Overall, the tolerability and safety of TOOKAD® Solu-
ble were considered satisfactory. The majority of TEAEs 
were mild or moderate and no patient who received the 
complete TOOKAD® Soluble procedure discontinued due 
to adverse effects. The most common TEAEs were dys-
uria, erectile dysfunction, and perineal pain. No signifi-
cant modification in vital signs was reported. There were 
eight SAEs in eight patients considered to be related to 
the study procedure, all of them resolved without seque-
lae. A part from two necrosis events caused by exces-
sive illumination due to device malfunction, most of the 
related SAEs were due to the insertion of the treatment 
needles and resolved in the days following the procedure 
without sequelae. For study PCM201 and PCM202, safety 
data were regularly reviewed by an independent Data and 
Safety Monitoring Board which did not identify any par-
ticular safety issue.
Even though most of the patients had no significant 
urinary symptoms at baseline, a reduction was seen in the 
IPSS questionnaire scores suggesting an improvement of 
urinary symptoms at month 6. The urinary catheter was 
successfully removed in the morning of the day following 
the procedure in the majority of patients treated. The results 
of the IIEF suggested a mild deterioration of the sexual 
quality of life of the patients. Post-procedural erectile dys-
function was reported as an AE in 16.2 % of patients fol-
lowing the TOOKAD® Soluble procedure, which compares 
favourably with a reported incidence of 30–80.0 % fol-
lowing radical treatments [20]. However, these results are 
difficult to analyse since many patients were not sexually 
active, and a longer follow-up would be needed to assess 
the real impact of the procedure on erectile function as 
erectile dysfunction tends to improve with time after a sur-
gical intervention.
Limitations to the pooled analysis
The studies contributing to the meta-analysis were carried 
out in men who had low-risk prostate cancer, which might 
be predominantly considered suitable for active surveil-
lance. Controversy continues to surround the need for inter-
vention in early-stage prostate cancer, and a recent publica-
tion of a randomised control of surgery versus observation 
(PIVOT) concluded that conservative management may be 
the most appropriate approach for such men [4]. However, 
as around two-thirds of men in the UK and a higher pro-
portion in Europe currently receive treatment for low-risk 
prostate cancer, it seems a reasonable patient population in 
which to explore the potential of a new treatment modality 
[18]. In order to further clarify a place for focal therapy, 
investigation in men with intermediate risk disease will be 
required.
Due to the limited sensitivity of TRUS biopsy, a nega-
tive biopsy at 6 months post-procedure does not necessarily 
confirm the absence of tumour. In the context of low-risk 
prostate cancer on standard TRUS biopsy, one in four men 
may have no cancer found on repeat TRUS, although one 
in four may be upgraded or upstaged [21]. We did consider 
using transperineal template guided biopsy both prior to 
and following the procedure, but decided that the require-
ment for an additional two general anaesthesia during a 
6-month study would be too great a burden for the patient.
This pooled analysis looked at outcomes based on a 
short follow-up of 6 months, and longer term histological 
results and patient reported outcomes are needed. Mean-
while, the time-scale does allow an assessment of the short- 
to medium-term toxicity profile of this procedure, which is 
sufficient to show the ability of TOOKAD® Soluble to reli-
ably eradicate malignant lesions.
Conclusions
This aim of this analysis of pooled data from three phases 
II studies was to evaluate further the efficacy and safety of 
a single dose of the recommended study drug and light dos-
age combination of TOOKAD® Soluble in the focal treat-
ment of patients with localized prostate cancer, 6 months 
after treatment. Negative biopsies were obtained in the 
majority of men at month 6. This negative biopsy rate 
improved further to 80.6 % in the 67 patients treated by 
hemiablation with LDI ≥ 1. The treatment was well toler-
ated. Further work to assess this within a European phase 
III randomized controlled trial comparing TOOKAD® 
Soluble to active surveillance (NCT01310894) is ongo-
ing, with recruitment of more than 400 men completed, 
as well as in a further phase III study in Latin America 
(NCT01875393).
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